Pernix Therapeutics Inc. to Present at JMP Securities Life Sciences Conference

MORRISTOWN, N.J., June 15, 2015 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (Nasdaq: PTX), a specialty pharmaceutical company, announced today that Doug Drysdale, Chairman, President and Chief Executive Officer, and Sanjay Patel, Chief Financial Officer, are scheduled to present at the JMP Securities Life Sciences Conference as follows:

The presentation will be webcast and available on the Investors section of the Company's website at http://www.pernixtx.com/investors/webcasts-presentations/. A replay of the webcast will be available for 30 days after the date of the presentation.

About Pernix Therapeutics

Pernix Therapeutics is a specialty pharmaceutical business with a focus on acquiring, developing and commercializing prescription drugs primarily for the U.S. market. The Company targets underserved therapeutic areas such as CNS, including neurology and pain management, and has an interest in expanding into additional specialty segments. The Company promotes its branded products to physicians through its two Pernix sales forces and markets its generic portfolio through its wholly owned subsidiaries, Macoven Pharmaceuticals, LLC and Cypress Pharmaceutical, Inc. To learn more about Pernix Therapeutics, visit www.pernixtx.com.

CONTACT: Investor Relations
         Lisa Wilson, (212) 452-2793
         In-Site Communications
         [email protected]

         Media Relations
         Marianne Lambertson, (800) 793-2145 ext. 1012
         Vice President, Marketing & Corporate Communications
         [email protected]

You May Also Be Interested In

• Pension Deductions Announces 2026 Cash Balance Plan Contribution Limits Table by Age and Compensation
• Faraday Future Announces This Week’s Investor Weekly Report From YT Jia Has Been Rescheduled to September 28; FF EAI “Built in USA” Upstream & Downstream Business Partner Conference Part Two
• Best Crypto Presale With a Catalyst This Week: DigiTap Sets September 30 Reveal After Raising $13M